Leap’s DKN-01 Enters Testing in Metastatic Castration-resistant Prostate Cancers

Leap’s DKN-01 Enters Testing in Metastatic Castration-resistant Prostate Cancers
Leap Therapeutics is launching a Phase 1/2 trial to study its lead candidate DKN-01, alone or in combination with chemotherapy, for the treatment of metastatic castration-resistant prostate cancer (CRPC) patients whose tumors have elevated Dickkopf-1 (DKK1) levels. The trial (NCT03837353), led by David Wise, MD, PhD, will be conducted at the Perlmutter Cancer Center at NYU Langone Health and is expected to begin around the end of March. "Patients with this type of prostate cancer have a very poor prognosis and may benefit from this new immunotherapy strategy targeting DKK1 therapy with
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *